Добавил:

Sekretar kiopkiopkiop18@yandex.ru t.me/Prokururor I Вовсе не секретарь, но почту проверяю Опубликованный материал нарушает ваши авторские права? Сообщите нам.

Вуз:

Ростовский Государственный Медицинский Университет

Предмет:

Медицина общая

Файл:

Книга_5368_Библиотеки_им_академика_М_И_Перельмана

.pdf

Скачиваний:

Добавлен:

02.09.2026

Размер:

21 Мб

Скачать

☆

<<< < Предыдущая 18 19 20 21 22 23 24 25 26 27 28 2930 / 5030 31 32 33 34 35 36 37 38 39 40 41 42 > Следующая >>>

282 A. Lalatsa et al.

https://t.me/med1917

Metab Dispos. 2009;37(12):2299–304. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=

Retrieve&db=PubMed&dopt=Citation&list_uids=19741036.

Boado RJ, Pardridge WM. Brain and organ uptake in the rhesus monkey in vivo of recombinant

iduronidase compared to an insulin receptor antibody-iduronidase fusion protein. Mol Pharm.

2017;14(4):1271–7. Boado RJ, Li JY, Nagaya M, Zhang C, Pardridge WM. Selective expression of the large neutral

amino acid transporter at the blood-brain barrier. Proc Natl Acad Sci USA. 1999;96(21):

12079–84. http://www.ncbi.nlm.nih.gov/pubmed/10518579. Boado RJ, Zhang Y, Zhang Y, Xia CF, Pardridge WM. Fusion antibody for Alzheimer’s disease

with bidirectional transport across the blood-brain barrier and abeta ﬁbril disaggregation.

Bioconjug Chem. 2007;18(2):447–55. https://doi.org/10.1021/bc060349x. Boado RJ, Hui EK, Lu JZ, Zhou QH, Pardridge WM. Selective targeting of a TNFR decoy receptor

pharmaceutical to the primate brain as a receptor-speciﬁc IgG fusion protein. J Biotechnol.

2010a;146(1–2):84–91. https://doi.org/10.1016/j.jbiotec.2010.01.011. Boado RJ, Zhou QH, Lu JZ, Hui EK, Pardridge WM. Pharmacokinetics and brain uptake of a

genetically engineered bifunctional fusion antibody targeting the mouse transferrin receptor.

Mol Pharm. 2010b;7(1):237–44. https://doi.org/10.1021/mp900235k. Bradbury MWB. The concept of the blood-brain barrier. Wiley; 1979. Bradbury MW. Transport of iron in the blood-brain-cerebrospinal ﬂuid system. J Neurochem.

1997;69(2):443–54. Broadwell RD, Balin BJ, Salcman M. Transcytotic pathway for blood-borne protein through the

blood-brain barrier. Proc Natl Acad Sci USA. 1988;85(2):632–6.

pubmed/2448779.

Butt AM, Jones HC, Abbott NJ. Electrical resistance across the blood-brain barrier in

anaesthetized rats: a developmental study. J Physiol. 1990;429:47–62.

nih.gov/pubmed/2277354.

Byeon HJ, Thao le Q, Lee S, Min SY, Lee ES, Shin BS, Choi HG, Youn YS. Doxorubicin-loaded

nanoparticles consisted of cationic- and mannose-modiﬁed-albumins for dual-targeting in brain

tumors. J Control Release. 2016;225:301–13. https://doi.org/10.1016/j.jconrel.2016.01.046. Carruthers A, DeZutter J, Ganguly A, Devaskar SU. Will the original glucose transporter isoform

please stand up! Am J Physiol Endocrinol Metab. 2009;297(4):E836–48.

1152/ajpendo.00496.2009.

Center for Drug Evaluation and Research (2022) Drug Products, Including Biological Products, that

Contain Nanomaterials – Guidance for Industry. Docket number: FDA-2017-D-0759, 20th

April 2022. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/drug-

products-includingbiological-products-contain-nanomaterials-guidance-industry

Chang R, Knox J, Chang J, Derbedrossian A, Vasilevko V, Cribbs D, Boado RJ, Pardridge WM,

Sumbria RK. Blood-brain barrier penetrating biologic TNF-alpha inhibitor for Alzheimer’s

disease. Mol Pharm. 2017;14(7):2340–9. Chen KT, Wei KC, Liu HL. Theranostic strategy of focused ultrasound induced blood-brain barrier

opening for CNS disease treatment. Front Pharmacol. 2019;10:86. https://doi.org/10.3389/

fphar.2019.00086.

Collaborators GN. Global, regional, and national burden of neurological disorders, 1990–2016: a

systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18(5):

459–80. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6459001/pdf/main.pdf. Daneman R, Zhou L, Kebede AA, Barres BA. Pericytes are required for blood-brain barrier

integrity during embryogenesis. Nature. 2010;468(7323):562–6. https://doi.org/10.1038/

nature09513.

Demeule M, Regina A, Che C, Poirier J, Nguyen T, Gabathuler R, Castaigne JP, Beliveau

R. Identiﬁcation and design of peptides as a new drug delivery system for the brain. J Pharmacol

Exp Ther. 2008;324(3):1064–72. https://doi.org/10.1124/jpet.107.131318. Demeule M, Beaudet N, Regina A, Besserer-Offroy E, Murza A, Tetreault P, Belleville K, Che C,

Larocque A, Thiot C, Beliveau R, Longpre JM, Marsault E, Leduc R, Lachowicz JE, Gonias SL,

https://doi.org/10.1021/acs.molpharmaceut.6b01166.

http://www.ncbi.nlm.nih.gov/pubmed/9231702.

http://www.ncbi.nlm.nih.gov/

http://www.ncbi.nlm.

https://doi.org/10.

https://doi.org/10.1021/acs.molpharmaceut.7b00200.

11 Nanomedicines for Delivery Across the Blood–Brain Barrier 283

https://t.me/med1917

Castaigne JP, Sarret P. Conjugation of a brain-penetrant peptide with neurotensin provides

antinociceptive properties. J Clin Invest. 2014;124(3):1199–213.

JCI70647.

Devaskar S, Zahm DS, Holtzclaw L, Chundu K, Wadzinski BE. Developmental regulation of the

distribution of rat brain insulin-insensitive (Glut 1) glucose transporter. Endocrinology.

1991;129(3):1530–40. https://doi.org/10.1210/endo-129-3-1530. Drin G, Cottin S, Blanc E, Rees AR, Temsamani J. Studies on the internalization mechanism of

cationic cell-penetrating peptides. J Biol Chem. 2003;278(33):31192–201.

1074/jbc.M303938200.

Eggimann GA, Buschor S, Darbre T, Reymond JL. Convergent synthesis and cellular uptake of

multivalent cell penetrating peptides derived from Tat, Antp, pVEC, TP10 and SAP. Org

Biomol Chem. 2013;11(39):6717–33. Ehrlich P. Das Sauerstoff-Bedürfniss des Organismus: eine farbenanalytische Studie; 1885. ElAli A, Hermann DM. ATP-binding cassette transporters and their roles in protecting the brain.

Neuroscientist. 2011;17(4):423 – 36. Estella-Hermoso de Mendoza A, Preat V, Mollinedo F, Blanco-Prieto MJ. In vitro and in vivo

efﬁcacy of edelfosine-loaded lipid nanoparticles against glioma. J Control Release. 2011;156

(3):421–6. https://doi.org/10.1016/j.jconrel.2011.07.030. [Record #672 is using a reference type

undeﬁned in this output style]. Fenstermacher J, Gross P, Sposito N, Acuff V, Pettersen S, Gruber K. Structural and functional

variations in capillary systems within the brain. Ann N Y Acad Sci. 1988;529:21–30.

www.ncbi.nlm.nih.gov/pubmed/3395069.

Fischer H, Gottschlich R, Seelig A. Blood-brain barrier permeation: molecular parameters

governing passive diffusion. J Membr Biol. 1998;165(3):201–11.

gov/pubmed/9767674.

Fong CW. Permeability of the blood-brain barrier: molecular mechanism of transport of drugs and

physiologically important compounds. J Membr Biol. 2015;248(4):651– 69.

1007/s00232-015-9778-9.

Frankel AD, Pabo CO. Cellular uptake of the tat protein from human immunodeﬁciency virus. Cell.

1988;55(6):1189–93. Friesema EC, Kuiper GG, Jansen J, Visser TJ, Kester MH. Thyroid hormone transport by the

human monocarboxylate transporter 8 and its rate-limiting role in intracellular metabolism. Mol

Endocrinol. 2006;20(11):2761–72. https://doi.org/10.1210/me.2005-0256. Furuse M, Hirase T, Itoh M, Nagafuchi A, Yonemura S, Tsukita S, Tsukita S. Occludin: a novel

integral membrane protein localizing at tight junctions. J Cell Biol. 1993;123(6 Pt 2):1777–88.

http://www.ncbi.nlm.nih.gov/pubmed/8276896.

Gaillard PJ, Appeldoorn CC, Dorland R, van Kregten J, Manca F, Vugts DJ, Windhorst B, van

Dongen GA, de Vries HE, Maussang D, van Tellingen O. Pharmacokinetics, brain delivery, and

efﬁcacy in brain tumor-bearing mice of glutathione pegylated liposomal doxorubicin (2B3-101).

PLoS One. 2014a;9(1):e82331. https://doi.org/10.1371/journal.pone.0082331. Gaillard PJ, Kerklaan BM, Aftimos P, Altintas S, Jager A, Gladdines W, Lonnqvist F, Soetekouw P,

Verheul H, Awada A, Schellens J, Brandsma D. Phase I dose escalating study of 2B3-101,

glutathione PEGylated liposomal doxorubicin, in patients with solid tumors and brain metasta-

ses or recurrent malignant glioma. Cancer Res. 2014b;74(19):CT216. https://doi.org/10.1158/

1538-7445.Am2014-Ct216.

Ganapathy V, Miyauchi S. Transport systems for opioid peptides in mammalian tissues. AAPS

J. 2005;7(4):E852–6. https://doi.org/10.1208/aapsj070482. Gao B, Stieger B, Noe B, Fritschy JM, Meier PJ. Localization of the organic anion transporting

polypeptide 2 (Oatp2) in capillary endothelium and choroid plexus epithelium of rat brain. J

Histochem Cytochem. 1999;47(10):1255–64. https://doi.org/10.1177/002215549904701005. Gao B, Hagenbuch B, Kullak-Ublick GA, Benke D, Aguzzi A, Meier PJ. Organic anion-

transporting polypeptides mediate transport of opioid peptides across blood-brain barrier. J

Pharmacol Exp Ther. 2000;294(1):73–9.

http://www.ncbi.nlm.nih.gov/pubmed/2849510.

https://doi.org/10.1039/c3ob41023d.

https://doi.org/10.1177/1073858410391270.

http://www.ncbi.nlm.nih.gov/pubmed/10871297.

https://doi.org/10.1172/

https://doi.org/10.

http://

http://www.ncbi.nlm.nih.

https://doi.org/10.

284 A. Lalatsa et al.

https://t.me/med1917

Gao X, Qian J, Zheng S, Xiong Y, Man J, Cao B, Wang L, Ju S, Li C. Up-regulating blood brain

barrier permeability of nanoparticles via multivalent effect. Pharm Res. 2013;30(10):2538–48.

https://doi.org/10.1007/s11095-013-1004-9.

Garrett NL, Lalatsa A, Uchegbu I, Schatzlein A, Moger J. Exploring uptake mechanisms of oral

nanomedicines using multimodal nonlinear optical microscopy. J Biophotonics. 2012;5(5–6):

458–68. https://doi.org/10.1002/jbio.201200006. Geldenhuys W, Mbimba T, Bui T, Harrison K, Sutariya V. Brain-targeted delivery of paclitaxel

using glutathione-coated nanoparticles for brain cancers. J Drug Target. 2011;19(9):837–45.

https://doi.org/10.3109/1061186X.2011.589435.

Gelperina SE, Khalansky AS, Skidan IN, Smirnova ZS, Bobruskin AI, Severin SE, Turowski B,

Zanella FE, Kreuter J. Toxicological studies of doxorubicin bound to polysorbate 80-coated

poly(butyl cyanoacrylate) nanoparticles in healthy rats and rats with intracranial glioblastoma.

Toxicol Lett. 2002;126(2):131–41. Geng Y, Dalhaimer P, Cai S, Tsai R, Tewari M, Minko T, Discher DE. Shape effects of ﬁlaments

versus spherical particles in ﬂow and drug delivery. Nat Nanotechnol. 2007;2(4):249–55.

https://doi.org/10.1038/nnano.2007.70.

Gleeson MP. Generation of a set of simple, interpretable ADMET rules of thumb. J Med Chem.

2008;51(4):817–34. Goldmann E. Vitalfarbung am zentralnervensystem. Abhandl Konigl preuss Akad Wiss. 1913;1:1–

60.

Goodwin JT, Clark DE. In silico predictions of blood-brain barrier penetration: considerations to

“keep in mind”. J Pharmacol Exp Ther. 2005;315(2):477–83.

075705.

Grabrucker AM, Ruozi B, Belletti D, Pederzoli F, Forni F, Vandelli MA, Tosi G. Nanoparticle

transport across the blood brain barrier. Tissue Barriers. 2016;4(1):e1153568.

1080/21688370.2016.1153568.

Greenwood J, Amos CL, Walters CE, Couraud PO, Lyck R, Engelhardt B, Adamson P. Intracellular

domain of brain endothelial intercellular adhesion molecule-1 is essential for T lymphocyte-

mediated signaling and migration. J Immunol. 2003;171(4):2099–108. http://www.ncbi.nlm.

nih.gov/pubmed/12902516.

Grifﬁths M, Yao SY, Abidi F, Phillips SE, Cass CE, Young JD, Baldwin SA. Molecular cloning

and characterization of a nitrobenzylthioinosine-insensitive (ei) equilibrative nucleoside trans-

porter from human placenta. Biochem J. 1997;328(Pt 3):739–43. http://www.ncbi.nlm.nih.gov/

pubmed/9396714.

Grube M, Kock K, Karner S, Reuther S, Ritter CA, Jedlitschky G, Kroemer HK. Modiﬁcation of

OATP2B1-mediated transport by steroid hormones. Mol Pharmacol. 2006;70(5):1735–41.

https://doi.org/10.1124/mol.106.026450.

Gulyaev AE, Gelperina SE, Skidan IN, Antropov AS, Kivman GY, Kreuter J. Signiﬁcant transport

of doxorubicin into the brain with polysorbate 80-coated nanoparticles. Pharm Res. 1999;16

(10):1564–9. https://doi.org/10.1023/a:1018983904537. Gustavsson A, Svensson M, Jacobi F, Allgulander C, Alonso J, Beghi E, Dodel R, Ekman M,

Faravelli C, Fratiglioni L, Gannon B, Jones DH, Jennum P, Jordanova A, Jonsson L,

Karampampa K, Knapp M, Kobelt G, Kurth T, Lieb R, Linde M, Ljungcrantz C,

Maercker A, Melin B, Moscarelli M, Musayev A, Norwood F, Preisig M, Pugliatti M,

Rehm J, Salvador-Carulla L, Schlehofer B, Simon R, Steinhausen HC, Stovner LJ, Vallat JM,

Van den Bergh P, os Van J, Vos P, Xu W, Wittchen HU, Jonsson B, Olesen J, Group, C. D. Cost

of disorders of the brain in Europe 2010. Eur Neuropsychopharmacol. 2011;21(10):718–

https://doi.org/10.1016/j.euroneuro.2011.08.008.

Hamilton NB, Attwell D, Hall CN. Pericyte-mediated regulation of capillary diameter: a component

of neurovascular coupling in health and disease. Front Neuroenerg. 2010;2:1453. https://doi.

org/10.3389/fnene.2010.00005.

Hawkins BT, Davis TP. The blood-brain barrier/neurovascular unit in health and disease.

Pharmacol Rev. 2005;57(2):173–85.

https://doi.org/10.1021/jm701122q.

https://doi.org/10.1016/s0378-4274(01)00456-8.

https://doi.org/10.1124/jpet.104.

https://doi.org/10.

79.

https://doi.org/10.1124/pr.57.2.4.

11 Nanomedicines for Delivery Across the Blood–Brain Barrier 285

https://t.me/med1917

Heidarzadeh M, Gursoy-Ozdemir Y, Kaya M, Eslami Abriz A, Zarebkohan A, Rahbarghazi R,

Sokullu E. Exosomal delivery of therapeutic modulators through the blood-brain barrier;

promise and pitfalls. Cell Biosci. 2021;11(1):142. Herz J, Marschang P. Coaxing the LDL receptor family into the fold. Cell. 2003;112(3):289–92.

http://www.ncbi.nlm.nih.gov/pubmed/12581519.

Heuer H, Maier MK, Iden S, Mittag J, Friesema EC, Visser TJ, Bauer K. The monocarboxylate

transporter 8 linked to human psychomotor retardation is highly expressed in thyroid hormone-

sensitive neuron populations. Endocrinology. 2005;146(4):1701–6. https://doi.org/10.1210/en.

2004-1179.

Huang R, Ke W, Han L, Liu Y, Shao K, Jiang C, Pei Y. Lactoferrin-modiﬁed nanoparticles could

mediate efﬁcient gene delivery to the brain in vivo. Brain Res Bull. 2010a;81(6):600–4.

doi.org/10.1016/j.brainresbull.2009.12.008.

Huang R, Ke W, Liu Y, Wu D, Feng L, Jiang C, Pei Y. Gene therapy using lactoferrin-modiﬁed

nanoparticles in a rotenone-induced chronic Parkinson model. J Neurol Sci. 2010b;290(1–2):

123–30. https://doi.org/10.1016/j.jns.2009.09.032. Hynynen K, McDannold N, Sheikov NA, Jolesz FA, Vykhodtseva N. Local and reversible blood-

brain barrier disruption by noninvasive focused ultrasound at frequencies suitable for trans-skull

sonications. NeuroImage. 2005;24(1):12–20. https://doi.org/10.1016/j.neuroimage.2004.

06.046.

Jiang T, Olson ES, Nguyen QT, Roy M, Jennings PA, Tsien RY. Tumor imaging by means of

proteolytic activation of cell-penetrating peptides. Proc Natl Acad Sci USA. 2004;101(51):

17867–72. https://doi.org/10.1073/pnas.0408191101. Jiang W, Kim BY, Rutka JT, Chan WC. Nanoparticle-mediated cellular response is size-dependent.

Nat Nanotechnol. 2008;3(3):145–50. Kafa H, Wang JT, Rubio N, Venner K, Anderson G, Pach E, Ballesteros B, Preston JE, Abbott NJ,

Al-Jamal KT. The interaction of carbon nanotubes with an in vitro blood-brain barrier model

and mouse brain in vivo. Biomaterials. 2015;53:437–52. https://doi.org/10.1016/j.biomaterials.

2015.02.083.

Kanazawa T, Akiyama F, Kakizaki S, Takashima Y, Seta Y. Delivery of siRNA to the brain using a

combination of nose-to-brain delivery and cell-penetrating peptide-modiﬁed nano-micelles.

Biomaterials. 2013;34(36):9220–6. https://doi.org/10.1016/j.biomaterials.2013.08.036. Kanhai KMS, Zuiker R, Stavrakaki I, Gladdines W, Gaillard PJ, Klaassen ES, Groeneveld

GJ. Glutathione-PEGylated liposomal methylprednisolone in comparison to free methylpred-

nisolone: slow release characteristics and prolonged lymphocyte depression in a ﬁrst-in-human

study. Br J Clin Pharmacol. 2018;84(5):1020–8. Kannan R, Mittur A, Bao Y, Tsuruo T, Kaplowitz N. GSH transport in immortalized mouse brain

endothelial cells: evidence for apical localization of a sodium-dependent GSH transporter. J

Neurochem. 1999;73(1):390–9. http://www.ncbi.nlm.nih.gov/pubmed/10386992. Karkan D, Pfeifer C, Vitalis TZ, Arthur G, Ujiie M, Chen Q, Tsai S, Koliatis G, Gabathuler R,

Jefferies WA. A unique carrier for delivery of therapeutic compounds beyond the blood-brain

barrier. PLoS One. 2008;3(6):e2469. https://doi.org/10.1371/journal.pone.0002469. Kèlder J, Grobtenhuis PD et al. Polar molecular surface as a dominating determinant for oral

absorption and brain penetration of drugs. Pharm Res 1999;16(10):1514–9. Kerklaan BM, Jager A, Aftimos P, Dieras V, Altintas S, Anders C, Arnedos M, Gelderblom H,

Soetekouw P, Gladdines W, Gaillard P, de Sousa C, Awada A, Schellens J, van Linde M,

Brandsma D. Phase 1/2a study of glutathione pegylated liposomal doxorubicin (2b3-101) in

breast cancer patients with brain metastases (Bcbm) or recurrent high-grade gliomas (Hgg).

Neuro-Oncology. 2014;16:163. https://doi.org/10.1093/neuonc/nou265.21. Kido Y, Tamai I, Okamoto M, Suzuki F, Tsuji A. Functional clariﬁcation of MCT1-mediated

transport of monocarboxylic acids at the blood-brain barrier using in vitro cultured cells and

in vivo BUI studies. Pharm Res. 2000;17(1):55–62.

714609.

https://doi.org/10.1038/nnano.2008.30.

https://doi.org/10.1186/s13578-021-00650-0.

https://

https://doi.org/10.1111/bcp.13525.

http://www.ncbi.nlm.nih.gov/pubmed/10

286 A. Lalatsa et al.

https://t.me/med1917

Kikuchi R, Kusuhara H, Sugiyama D, Sugiyama Y. Contribution of organic anion transporter

3 (Slc22a8) to the elimination of p-aminohippuric acid and benzylpenicillin across the blood-

brain barrier. J Pharmacol Exp Ther. 2003;306(1):51–8.

049197.

Kim B, Han G, Toley BJ, Kim CK, Rotello VM, Forbes NS. Tuning payload delivery in tumour

cylindroids using gold nanoparticles. Nat Nanotechnol. 2010;5(6):465–72.

1038/nnano.2010.58.

Kinoshita M, McDannold N, Jolesz FA, Hynynen K. Noninvasive localized delivery of Herceptin

to the mouse brain by MRI-guided focused ultrasound-induced blood-brain barrier disruption.

Proc Natl Acad Sci USA. 2006;103(31):11719–23. https://doi.org/10.1073/pnas.0604318103. Kniesel U, Wolburg H. Tight junctions of the blood-brain barrier. Cell Mol Neurobiol. 2000;20(1):

57–76. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov.

Komura J, Tamai I, Senmaru M, Terasaki T, Sai Y, Tsuji A. Sodium and chloride ion-dependent

Kreuter J. Drug delivery to the central nervous system by polymeric nanoparticles: what do

Kumagai AK, Eisenberg JB, Pardridge WM. Absorptive-mediated endocytosis of cationized

Kumagai AK, Dwyer KJ, Pardridge WM. Differential glycosylation of the GLUT1 glucose

Kumar P, Wu H, McBride JL, Jung KE, Kim MH, Davidson BL, Lee SK, Shankar P, Manjunath

Kuo YC, Wang IH, Rajesh R. Use of leptin-conjugated phosphatidic acid liposomes with resver-

Kurihara A, Pardridge WM. Abeta(1-40) peptide radiopharmaceuticals for brain amyloid imaging:

Kusuhara H, Sekine T, Utsunomiya-Tate N, Tsuda M, Kojima R, Cha SH, Sugiyama Y, Kanai Y,

Lalatsa A, Butt AM. Physiology of the blood–brain barrier and mechanisms of transport across the

Lalatsa A, Garrett NL, Ferrarelli T, Moger J, Schatzlein AG, Uchegbu IF. Delivery of peptides to

Lalatsa A, Lee V, Malkinson JP, Zloh M, Schatzlein AG, Uchegbu IF. A prodrug nanoparticle

Lalatsa A, Schatzlein A, Uchegbu I. Nanostructures overcoming the blood-brain barrier: physio-

http://www.ncbi.nlm.nih.gov/pubmed/10690502.

2004;3(8):711–5.

transport of beta-alanine across the blood-brain barrier. J Neurochem. 1996;67(1):330–5.

www.ncbi.nlm.nih.gov/pubmed/8667010.

we know? Adv Drug Deliv Rev. 2014;71:2–14.

albumin and a beta-endorphin-cationized albumin chimeric peptide by isolated brain capillaries.

Model system of blood-brain barrier transport. J Biol Chem. 1987;262(31):15214–9. http://

www.ncbi.nlm.nih.gov/pubmed/2959663.

transporter in brain capillaries and choroid plexus. Biochim Biophys Acta. 1994;1193(1):

24–30. http://www.ncbi.nlm.nih.gov/pubmed/8038191.

N. Transvascular delivery of small interfering RNA to the central nervous system. Nature.

2007;448(7149):39–43. https://doi.org/10.1038/nature05901.

atrol and epigallocatechin gallate to protect dopaminergic neurons against apoptosis for

Parkinson’s disease therapy. Acta Biomater. 2021;119:360– 74. https://doi.org/10.1016/j.

actbio.2020.11.015.

(111)In chelation, conjugation to poly(ethylene glycol)-biotin linkers, and autoradiography with

Alzheimer’sdisease brainsections.Bioconjug Chem. 2000;11(3):380–6.http://www.ncbi.nlm.nih.

gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10821654.

Endou H. Molecular cloning and characterization of a new multispeciﬁc organic anion trans-

porter from rat brain. J Biol Chem. 1999;274(19):13675–80. http://www.ncbi.nlm.nih.gov/

pubmed/10224140.

BBB. In: Kesharwani P, Gupta U, editors. Nanotechnology-based targeted drug delivery

systems for brain tumors. 1st ed. Academic Press; 2018. p. 49–74. https://doi.org/10.1016/

C2016-0-03390-9.

the blood and brain after oral uptake of quaternary ammonium palmitoyl glycol chitosan

nanoparticles. Mol Pharm. 2012a;9(6):1764–74. https://doi.org/10.1021/mp300068j.

approach for the oral delivery of a hydrophilic peptide, leucine(5)-enkephalin, to the brain. Mol

Pharm. 2012b;9(6):1665–80. https://doi.org/10.1021/mp300009u.

logical considerations and mechanistic issues. In: Alonso MJ, Csaba NS, editors.

https://doi.org/10.1038/nrd1470.

https://doi.org/10.1016/j.addr.2013.08.008.

https://doi.org/10.1124/jpet.103.

https://doi.org/10.

http://

11 Nanomedicines for Delivery Across the Blood–Brain Barrier 287

https://t.me/med1917

Nanostructured biomaterials for overcoming biological barriers. RSC Publishing;

2012c. p. 329–63. Lalatsa A, Schatzlein AG, Uchegbu IF. Strategies to deliver peptide drugs to the brain. Mol Pharm.

2014;11(4):1081–93. Lalatsa A, Leite DM, Pilkington GJ. Nanomedicines and the Future of Glioma. Oncol News.

2015a;10(2):16–21. Lalatsa A, Schatzlein AG, Garrett NL, Moger J, Briggs M, Godfrey L, Iannitelli A, Freeman J,

Uchegbu IF. Chitosan amphiphile coating of peptide nanoﬁbres reduces liver uptake and

delivers the peptide to the brain on intravenous administration. J Control Release. 2015b;197:

87–96. Lapin NA, Gill K, Shah BR, Chopra R. Consistent opening of the blood brain barrier using focused

Laschinger M, Engelhardt B. Interaction of alpha4-integrin with VCAM-1 is involved in adhesion

Lee HJ, Pardridge WM. Pharmacokinetics and delivery of tat and tat-protein conjugates to tissues

Lee Y, Kim M, Ha J, Lee M. Brain-targetedicroﬂuidic manufacture of lipid-based nanomedicines

Leite DM, Barbu E, Pilkington GJ, Lalatsa A. Peptide self-assemblies for drug delivery. Curr Top

Lennernas H, Lundgren E. Intestinal and blood-brain drug transport: beyond involvement of a

Liu QR, Lopez-Corcuera B, Mandiyan S, Nelson H, Nelson N. Molecular characterization of four

Liu Y, Li J, Shao K, Huang R, Ye L, Lou J, Jiang C. A leptin derived 30-amino-acid peptide

Liu M, Apriceno A, Sipin M, Scarpa E, Rodriguez-Arco L, Poma A, Marchello G, Battaglia G,

Loscher W, Potschka H. Blood-brain barrier active efﬂux transporters: ATP-binding cassette gene

Loscher W, Potschka H. Drug resistance in brain diseases and the role of drug efﬂux transporters.

Loscher W, Potschka H. Role of drug efﬂux transporters in the brain for drug disposition and

Lu H, Chen C, Klaassen C. Tissue distribution of concentrative and equilibrative nucleoside

Lu W, Zhang Y, Tan YZ, Hu KL, Jiang XG, Fu SK. Cationic albumin-conjugated pegylated

https://doi.org/10.1016/j.jconrel.2014.10.028.

ultrasound with constant intravenous infusion of microbubble agent. Sci Rep. 2020;10(1):

16546. https://doi.org/10.1038/s41598-020-73312-9.

of encephalitogenic T cell blasts to brain endothelium but not in their transendothelial migration

in vitro. J Neuroimmunol. 2000;102(1):32–43. http://www.ncbi.nlm.nih.gov/pubmed/1062

6664.

in vivo. Bioconjug Chem. 2001;12(6):995–9.

cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11716691.

exosome-mimetic cell membrane nanovesicles with therapeutic oligonucleotides elicit anti-

tumor effects in glioblastoma animal models. Bioeng Transl Med. 2022;8(2):e10426. https://

doi.org/10.1002/btm2.10426.

Med Chem. 2015;15(22):2277–89.

single transport function. Drug Discov Today Technol. 2004;1(4):417–22.

pharmacologically distinct gamma-aminobutyric acid transporters in mouse brain [corrected]. J

Biol Chem. 1993;268(3):2106–12. http://www.ncbi.nlm.nih.gov/pubmed/8420981.

modiﬁed pegylated poly-L-lysine dendrigraft for brain targeted gene delivery. Biomaterials.

2010;31(19):5246–57. https://doi.org/10.1016/j.biomaterials.2010.03.011.

Angioletti-Uberti S. Combinatorial entropy behaviour leads to range selective binding in ligand-

receptor interactions. Nat Commun. 2020;11(1):4836. https://doi.org/10.1038/s41467-020-

18603-5.

family. NeuroRx. 2005a;2(1):86–98.

Nat Rev Neurosci. 2005b;6(8):591–602.

treatment of brain diseases. Prog Neurobiol. 2005c;76(1):22–76.

pneurobio.2005.04.006.

transporters in male and female rats and mice. Drug Metab Dispos. 2004;32(12):1455–61.

https://doi.org/10.1124/dmd.104.001123.

nanoparticles as novel drug carrier for brain delivery. J Control Release. 2005;107(3):428–48.

https://doi.org/10.1016/j.jconrel.2005.03.027.

https://doi.org/10.1039/9781849735292-00329.

https://doi.org/10.1021/mp400680d.

https://issuu.com/oncologynews/docs/010515.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?

http://www.ncbi.nlm.nih.gov/pubmed/26043734.

https://doi.org/10.1602/neurorx.2.1.86

https://doi.org/10.1038/nrn1728.

https://doi.org/10.1016/j.

288 A. Lalatsa et al.

https://t.me/med1917

Lu F, Pang Z, Zhao J, Jin K, Li H, Pang Q, Zhang L, Pang Z. Angiopep-2-conjugated poly(ethylene

glycol)-co- poly(epsilon-caprolactone) polymersomes for dual-targeting drug delivery to glioma

in rats. Int J Nanomedicine. 2017;12:2117–27. Lu H, Chen T, Wang Y, He Y, Pang Z, Wang Y. Dual targeting micelles loaded with paclitaxel and

lapatinib for combinational therapy of brain metastases from breast cancer. Sci Rep. 2022;12(1):

2610. https://doi.org/10.1038/s41598-022-06677-8.

Maresh GA, Kastin AJ, Brown TT, Zadina JE, Banks WA. Peptide transport system-1 (PTS-1) for

Tyr-MIF-1 and Met-enkephalin differs from the receptors for either. Brain Res. 1999;839(2):

336–40. http://www.ncbi.nlm.nih.gov/pubmed/10519058. Masserini M. Nanoparticles for brain drug delivery. ISRN Biochem. 2013;2013:238428. https://doi.

org/10.1155/2013/238428.

Matsumoto J, Stewart T, Sheng L, Li N, Bullock K, Song N, Shi M, Banks WA, Zhang

J. Transmission of alpha-synuclein-containing erythrocyte-derived extracellular vesicles across

the blood-brain barrier via adsorptive-mediated transcytosis: another mechanism for initiation

and progression of Parkinson’s disease? Acta Neuropathol Commun. 2017;5(1):71.

org/10.1186/s40478-017-0470-4.

Maussang D, Rip J, van Kregten J, van den Heuvel A, van der Pol S, van der Boom B, Reijerkerk A,

Chen L, de Boer M, Gaillard P, de Vries H. Glutathione conjugation dose-dependently increases

brain-speciﬁc liposomal drug delivery in vitro and in vivo. Drug Discov Today Technol.

2016;20:59–69. Mazza M, Notman R, Anwar J, Rodger A, Hicks M, Parkinson G, McCarthy D, Daviter T, Moger J,

Garrett N, Mead T, Briggs M, Schatzlein AG, Uchegbu IF. Nanoﬁber-based delivery of

therapeutic peptides to the brain. ACS Nano. 2013;7(2):1016–26. https://doi.org/10.1021/

nn305193d.

Misra A, Ganesh S, Shahiwala A, Shah SP. Drug delivery to the central nervous system: a review. J

Pharm Pharm Sci. 2003;6(2):252–73. Moos T, Morgan EH. Restricted transport of anti-transferrin receptor antibody (OX26) through the

blood-brain barrier in the rat. J Neurochem. 2001;79(1):119–29.

pubmed/11595764.

Nance EA, Woodworth GF, Sailor KA, Shih TY, Xu Q, Swaminathan G, Xiang D, Eberhart C,

Hanes J. A dense poly(ethylene glycol) coating improves penetration of large polymeric

nanoparticles within brain tissue. Sci Transl Med. 2012;4(149):149ra119. https://doi.org/10.

1126/scitranslmed.3003594.

Nozawa T, Imai K, Nezu J, Tsuji A, Tamai I. Functional characterization of pH-sensitive organic

anion transporting polypeptide OATP-B in human. J Pharmacol Exp Ther. 2004;308(2):

438–45. https://doi.org/10.1124/jpet.103.060194. Ohtsuki S, Asaba H, Takanaga H, Deguchi T, Hosoya K, Otagiri M, Terasaki T. Role of blood-brain

barrier organic anion transporter 3 (OAT3) in the efﬂ ux of indoxyl sulfate, a uremic toxin: its

involvement in neurotransmitter metabolite clearance from the brain. J Neurochem. 2002;83(1):

57–66. http://www.ncbi.nlm.nih.gov/pubmed/12358729. Oldendorf WH. Carrier-mediated blood-brain barrier transport of short-chain monocarboxylic

organic acids. Am J Physiol. 1973;224(6):1450–3. Oldendorf WH. The blood-brain barrier. Exp Eye Res. 1977;25(Suppl):177–90. http://www.ncbi.

nlm.nih.gov/pubmed/338316.

Oldendorf WH, Szabo J. Amino acid assignment to one of three blood-brain barrier amino acid

carriers. Am J Phys. 1976;230(1):94–8. http://www.ncbi.nlm.nih.gov/pubmed/1251917. Oldendorf WH, Cornford ME, Brown WJ. The large apparent work capability of the blood-brain

barrier: a study of the mitochondrial content of capillary endothelial cells in brain and other

tissues of the rat. Ann Neurol. 1977;1(5):409–17. https://doi.org/10.1002/ana.410010502. Osouli-Bostanabad K, Puliga S, Serrano DR, Bucchi A, Halbert G, Lalatsa A. Microﬂuidic

manufacture of lipid-based nanomedicines. Pharmaceutics. 2022;14(9):1940.

10.3390/pharmaceutics14091940.

https://doi.org/10.1016/j.ddtec.2016.09.003.

http://www.ncbi.nlm.nih.gov/pubmed/12935438.

https://doi.org/10.2147/IJN.S123422.

https://doi.

http://www.ncbi.nlm.nih.gov/

https://doi.org/

11 Nanomedicines for Delivery Across the Blood–Brain Barrier 289

https://t.me/med1917

Owens DE 3rd, Peppas NA. Opsonization, biodistribution, and pharmacokinetics of polymeric

nanoparticles. Int J Pharm. 2006;307(1):93–102. Pajouhesh H, Lenz GR. Medicinal chemical properties of successful central nervous system drugs. J

Am Soc Exp Neuro Therapeutic. 2005;2:541. Pardridge WM. The blood-brain barrier: bottleneck in brain drug development. NeuroRx. 2005;2

(1):3–14. Pardridge WM. Brain drug development and brain drug targeting. Pharm Res. 2007a;24(9):

1729–32. Pardridge WM. shRNA and siRNA delivery to the brain. Adv Drug Deliv Rev. 2007b;59(2–3):

141–52. Pardridge WM. Drug transport across the blood–brain barrier. J Cereb Blood Flow Metab. 2012;32

(11):1959–72. Pardridge WM, Boado RJ. Enhanced cellular uptake of biotinylated antisense oligonucleotide or

peptide mediated by avidin, a cationic protein. FEBS Lett. 1991;288(1–2):30–2.

ncbi.nlm.nih.gov/pubmed/1879560.

Pardridge WM, Boado RJ. Fusion proteins for delivery of GDNF to the CNS. Patent Application,

WO/2009/070597. 2009.

9070597&recNum=1&docAn= US2008084718&queryString= FP:(wo/2009/070597)&

maxRec=1 (60/990,290 26.11.2007 US 11/245,546 07.10.2005 US (IA Considered Withdrawn

24.02.2009)).

Pardridge WM, Boado RJ. Compositions and methods for blood-brain barrier delivery of

IGG-decoy receptor fusion proteins. Patent Application, WO/2010/108048. 2010a.

www.wipo.int/patentscope/search/en/detail.jsf?docId=WO2010 108048&recNum= 1&

docAn=US2010027882&queryString=FP:(WO/2010/108048)&maxRec=1.

Pardridge WM, Boado RJ. Methods and compositions for increasing iduronate 2-sulfatase activity

in the CNS. Patent Application, WO/2011/044542. 2010b.

search/en/detail.jsf?docId= WO2011044542&recNum=1&maxRec= 1&ofﬁ ce=&

prevFilter=&sortOption=&queryString=FP%3A%28WO%2F2011%2F044542%29&tab=

PCT+Biblio (61/256,049 29.10.2009 US 61/250,378 09.10.2009 US).

Pardridge WM, Boado RJ. Fusion proteins for delivery of erythropoetin to the CNS. Patent

Application, WO/2011/088409. 2011.

docId=WO2011088409&recNum= 1&tab=PCTDocuments&maxRec=1&ofﬁce= null&

prevFilter=null&sortOption=null&queryString=FP%3A%28wo%2F2011%2F088409%29.

Pardridge WM, Triguero D, Buciak J. Transport of histone through the blood-brain barrier. J

Pharmacol Exp Ther. 1989;251(3):821–6. Pardridge WM, Boado RJ, Farrell CR. Brain-type glucose transporter (GLUT-1) is selectively

localized to the blood-brain barrier. Studies with quantitative western blotting and in situ

hybridization. J Biol Chem. 1990a;265(29):18035–40. https://www.ncbi.nlm.nih.gov/

pubmed/2211679.

Pardridge WM, Triguero D, Buciak J, Yang J. Evaluation of cationized rat albumin as a potential

blood-brain barrier drug transport vector. J Pharmacol Exp Ther. 1990b;255(2):893–9. http://

www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=Pub Med&dopt=Citation&list_

uids=2243356.

Petri B, Bootz A, Khalansky A, Hekmatara T, Muller R, Uhl R, Kreuter J, Gelperina

S. Chemotherapy of brain tumour using doxorubicin bound to surfactant-coated poly(butyl

cyanoacrylate) nanoparticles: revisiting the role of surfactants. J Control Release. 2007;117(1):

51–8. https://doi.org/10.1016/j.jconrel.2006.10.015. Pham W, Zhao BQ, Lo EH, Medarova Z, Rosen B, Moore A. Crossing the blood-brain barrier: a

potential application of myristoylated polyarginine for in vivo neuroimaging. NeuroImage.

2005;28(1):287–92. https://doi.org/10.1016/j.neuroimage.2005.06.007. Poduslo JF, Curran GL, Gill JS. Putrescine-modiﬁed nerve growth factor: bioactivity, plasma

pharmacokinetics, blood-brain/nerve barrier permeability, and nervous system biodistribution.

https://doi.org/10.1602/neurorx.2.1.3.

https://doi.org/10.1007/s11095-007-9387-0.

https://doi.org/10.1016/j.addr.2007.03.008.

https://doi.org/10.1038/jcbfm.2012.126.

http://www.wipo.int/patentscope/search/en/detail.jsf?docId=WO200

https://doi.org/10.1016/j.ijpharm.2005.10.010.

http://www.

http://

http://www.wipo.int/patentscope/

http://www.wipo.int/patentscope/search/en/detail.jsf?

http://www.ncbi.nlm.nih.gov/pubmed/2600816.

290 A. Lalatsa et al.

https://t.me/med1917

J Neurochem. 1998;71(4):1651–60. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=

Retrieve&db=PubMed&dopt=Citation&list_uids=9751199.

Pulford B, Reim N, Bell A, Veatch J, Forster G, Bender H, Meyerett C, Hafeman S, Michel B,

Johnson T, Wyckoff AC, Miele G, Julius C, Kranich J, Schenkel A, Dow S, Zabel

MD. Liposome-siRNA-peptide complexes cross the blood-brain barrier and signiﬁcantly

decrease PrP on neuronal cells and PrP in infected cell cultures. PLoS One. 2010;5(6):

https://doi.org/10.1371/journal.pone.0011085.

e11085. Rebeck GW, Reiter JS, Strickland DK, Hyman BT. Apolipoprotein E in sporadic Alzheimer’s

disease: allelic variation and receptor interactions. Neuron. 1993;11(4):575–80.

ncbi.nlm.nih.gov/pubmed/8398148.

Regina A, Demeule M, Tripathy S, Lord-Dufour S, Currie JC, Iddir M, Annabi B, Castaigne JP,

Lachowicz JE. ANG4043, a novel brain-penetrant peptide-mAb conjugate, is efﬁcacious against

HER2-positive intracranial tumors in mice. Mol Cancer Ther. 2015;14(1):129–40. https://doi.

org/10.1158/1535-7163.MCT-14-0399.

Reichel C, Gao B, Van Montfoort J, Cattori V, Rahner C, Hagenbuch B, Stieger B, Kamisako T,

Meier PJ. Localization and function of the organic anion-transporting polypeptide Oatp2 in rat

liver. Gastroenterology. 1999;117(3):688–95. http://www.ncbi.nlm.nih.gov/pubmed/1046414

Roberts LM, Woodford K, Zhou M, Black DS, Haggerty JE, Tate EH, Grindstaff KK,

Mengesha W, Raman C, Zerangue N. Expression of the thyroid hormone transporters

monocarboxylate transporter-8 (SLC16A2) and organic ion transporter-14 (SLCO1C1) at the

blood-brain barrier. Endocrinology. 2008;149(12):6251–61.

2008-0378.

Sanchez del Pino MM, Hawkins RA, Peterson DR. Neutral amino acid transport by the blood-brain

barrier. Membrane vesicle studies. J Biol Chem. 1992;267(36):25951–7.

nih.gov/pubmed/1464608.

Sauer I, Dunay IR, Weisgraber K, Bienert M, Dathe M. An apolipoprotein E-derived peptide

mediates uptake of sterically stabilized liposomes into brain capillary endothelial cells. Bio-

chemistry. 2005;44(6):2021–9. https://doi.org/10.1021/bi048080x. Sauer I, Nikolenko H, Keller S, Abu Ajaj K, Bienert M, Dathe M. Dipalmitoylation of a cellular

uptake-mediating apolipoprotein E-derived peptide as a promising modiﬁcation for stable

anchorage in liposomal drug carriers. Biochim Biophys Acta. 2006;1758(4):552–61. http://

www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=Pub Med&dopt=Citation&list_

uids=16681993.

Schenk GJ, Haasnoot PC, Centlivre M, Legrand N, Rip J, de Boer AG, Berkhout B. Efﬁcient

CRM197-mediated drug targeting to monocytes. J Control Release. 2012;158(1):139–47.

https://doi.org/10.1016/j.jconrel.2011.09.091.

Schirmacher A, Winters S, Fischer S, Goeke J, Galla HJ, Kullnick U, Ringelstein EB, Stogbauer

F. Electromagnetic ﬁelds (1.8 GHz) increase the permeability to sucrose of the blood-brain

barrier in vitro. Bioelectromagnetics. 2000;21(5):338

pubmed/10899769.

Schmidt N, Mishra A, Lai GH, Wong GC. Arginine-rich cell-penetrating peptides. FEBS Lett.

2010;584(9):1806–13. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=

PubMed&dopt=Citation&list_uids=19925791.

Schroeder U, Sommerfeld P, Sabel BA. Efﬁcacy of oral dalargin-loaded nanoparticle delivery

across the blood-brain barrier. Peptides. 1998;19(4):777–80. https://doi.org/10.1016/s0196-

9781(97)00474-9.

Sedlakova R, Shivers RR, Del Maestro RF. Ultrastructure of the blood-brain barrier in the rabbit. J

Submicrosc Cytol Pathol. 1999;31(1):149–61. http://www.ncbi.nlm.nih.gov/pubmed/10363362

. Serrano Lopez DR, Lalatsa A. Peptide pills for brain diseases? Reality and future perspectives. Ther

Deliv. 2013;4(4):479–501.

https://doi.org/10.4155/tde.13.5.

https://doi.org/10.1210/en.

http://www.ncbi.nlm.

http://www.ncbi.nlm.nih.gov/

–45.

http://www.

11 Nanomedicines for Delivery Across the Blood–Brain Barrier 291

https://t.me/med1917

Shen S, Zhang W. ABC transporters and drug efﬂux at the blood-brain barrier. Rev Neurosci.

2010;21(1):29–53. Shen S, Callaghan D, Juzwik C, Xiong H, Huang P, Zhang W. ABCG2 reduces ROS-mediated

toxicity and inﬂammation: a potential role in Alzheimer’s disease. J Neurochem. 2010;114(6):

1590–604. https://doi.org/10.1111/j.1471-4159.2010.06887.x. Shepro D, Morel NM. Pericyte physiology. FASEB J. 1993;7(11):1031–8. http://www.ncbi.nlm.

nih.gov/pubmed/8370472.

Shi N, Zhang Y, Zhu C, Boado RJ, Pardridge WM. Brain-speciﬁc expression of an exogenous gene

after i.v. administration. Proc Natl Acad Sci USA. 2001;98(22):12754–9.

1073/pnas.221450098.

Simpson IA, Appel NM, Hokari M, Oki J, Holman GD, Maher F, Koehler-Stec EM, Vannucci SJ,

Smith QR. Blood-brain barrier glucose transporter: effects of hypo- and hyperglycemia

revisited. J Neurochem. 1999;72(1):238–47. http://www.ncbi.nlm.nih.gov/pubmed/9886075. Simpson IA, Vannucci SJ, DeJoseph MR, Hawkins RA. Glucose transporter asymmetries in the

bovine blood-brain barrier. J Biol Chem. 2001;276(16):12725–9.

M010897200.

Smith QR. Transport of glutamate and other amino acids at the blood-brain barrier. J Nutr.

2000;130(4S Suppl):1016S–22S. Spencer BJ, Verma IM. Targeted delivery of proteins across the blood-brain barrier. Proc Natl Acad

Sci USA. 2007;104(18):7594–9.

Retrieve&db=PubMed&dopt=Citation&list_uids=17463083.

Sugiyama D, Kusuhara H, Shitara Y, Abe T, Meier PJ, Sekine T, Endou H, Suzuki H, Sugiyama

Y. Characterization of the efﬂux transport of 17beta-estradiol-D-17beta-glucuronide from the

brain across the blood-brain barrier. J Pharmacol Exp Ther. 2001;298(1):316–22. http://www.

ncbi.nlm.nih.gov/pubmed/11408557.

Tamai I, Senmaru M, Terasaki T, Tsuji A. Na(+)- and Cl(-)-dependent transport of taurine at the

blood-brain barrier. Biochem Pharmacol. 1995;50(11):1783–93.

pubmed/8615856.

Tamai I, Ohashi R, Nezu J, Yabuuchi H, Oku A, Shimane M, Sai Y, Tsuji A. Molecular and

functional identiﬁcation of sodium ion-dependent, high afﬁnity human carnitine transporter

OCTN2. J Biol Chem. 1998;273(32):20378–82. http://www.ncbi.nlm.nih.gov/pubmed/96853

90.

Terasaki T, Hosoya K. The blood-brain barrier efﬂux transporters as a detoxifying system for the

brain. Adv Drug Deliv Rev. 1999;36(2–3):195–209.

837716.

Terasaki T, Deguchi Y, Sato H, Hirai K, Tsuji A. In vivo transport of a dynorphin-like analgesic

peptide, E-2078, through the blood-brain barrier: an application of brain microdialysis. Pharm

Res. 1991;8(7):815–20. http://www.ncbi.nlm.nih.gov/pubmed/1681528. Thomas SA, Abbruscato TJ, Hruby VJ, Davis TP. The entry of [D-penicillamine2,5]enkephalin into

the central nervous system: saturation kinetics and speciﬁcity. J Pharmacol Exp Ther. 1997;280

(3):1235–40. http://www.ncbi.nlm.nih.gov/pubmed/9067309. Tian X, Leite DM, Scarpa E, Nyberg S, Fullstone G, Forth J, Matias D, Apriceno A, Poma A, Duro-

Castano A, Vuyyuru M, Harker-Kirschneck L, Saric A, Zhang Z, Xiang P, Fang B, Tian Y,

Luo L, Rizzello L, Battaglia G. On the shuttling across the blood-brain barrier via tubule

formation: mechanism and cargo avidity bias. Sci Adv. 2020;6(48):eabc4397. https://doi.org/

10.1126/sciadv.abc4397.

Triguero D, Buciak JB, Yang J, Pardridge WM. Blood-brain barrier transport of cationized

immunoglobulin G: enhanced delivery compared to native protein. Proc Natl Acad Sci USA.

1989;86(12):4761–5. http://www.ncbi.nlm.nih.gov/pubmed/2734318. Vera JC, Rivas CI, Fischbarg J, Golde DW. Mammalian facilitative hexose transporters mediate the

transport of dehydroascorbic acid. Nature. 1993;364(6432):79–82.

364079a0.

http://www.ncbi.nlm.nih.gov/pubmed/20458886.

https://doi.org/10.

https://doi.org/10.1074/jbc.

http://www.ncbi.nlm.nih.gov/pubmed/10736373.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=

http://www.ncbi.nlm.nih.gov/

http://www.ncbi.nlm.nih.gov/pubmed/10

https://doi.org/10.1038/

<<< < Предыдущая 18 19 20 21 22 23 24 25 26 27 28 2930 / 5030 31 32 33 34 35 36 37 38 39 40 41 42 > Следующая >>>

Соседние файлы в папке Библиотека им академика М.И. Перельмана

#
31.08.202622 Мб0Книга_5363_Библиотеки_им_академика_М_И_Перельмана.pdf
#
02.09.202621 Мб0Книга_5364_Библиотеки_им_академика_М_И_Перельмана.pdf
#
02.09.202621 Мб0Книга_5365_Библиотеки_им_академика_М_И_Перельмана.pdf
#
02.09.202621 Мб0Книга_5366_Библиотеки_им_академика_М_И_Перельмана.pdf
#
02.09.202621 Мб0Книга_5367_Библиотеки_им_академика_М_И_Перельмана.pdf
#
02.09.202621 Мб0Книга_5368_Библиотеки_им_академика_М_И_Перельмана.pdf
#
02.09.202620 Мб0Книга_5369_Библиотеки_им_академика_М_И_Перельмана.pdf
#
29.08.202686 Мб0Книга_537_Библиотеки_им_академика_М_И_Перельмана.pdf
#
02.09.202620 Мб0Книга_5370_Библиотеки_им_академика_М_И_Перельмана.pdf
#
02.09.202619 Мб0Книга_5371_Библиотеки_им_академика_М_И_Перельмана.pdf
#
02.09.202619 Мб0Книга_5372_Библиотеки_им_академика_М_И_Перельмана.pdf